RVVCRiver Valley Vision Centers (Minnesota)
RVVCRecurrent Idiopathic Vulvovaginal Candidiasis
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
'Joining a company that is paving the path for a potential new treatment paradigm for millions of people living with RVVC and other fungal diseases is a tremendous opportunity,' said Ms.
It received FDA Qualified Infectious Disease Product and Fast-Track designations to support its potential as the first FDA-approved treatment for RVVC.
Wagner et al., "Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA," Health and Quality of Life Outcomes, vol.
Some patients of RVVC may benefit from once weekly fluconazole (200mg) for 8 weeks, followed by fortnightly administration for 4 months, and monthly dosage for the next 6 months ( Donders' regime).8
A comparison of vaginal nystatin and oral fluconazole for treating RVVC was performed in a recent study on 293 patients by a Chinese research group (23).
A vaginal culture to test for Candida may also be considered and should be obtained from patients with RVVC to confirm the clinical diagnosis and to identify unusual species (including non-Calbicans species), particularly Candida glabrata.
About 5 to 8 percent of women experience recurrent vulvovaginal candidiasis (RVVC), defined as four or more yeast infections per year.
RVVC impacts quality of life, to a degree comparable to asthma and worse than diseases such as headache and migraine, yet despite the high prevalence, there are currently no agents in the United States approved to treat the condition.
An estimated 5-8% of women of child-bearing age suffer from recurring episodes of acute vulvovaginal candidiasis, a syndrome termed RVVC. There are currently no approved agents in the United States to prevent these recurring and difficult to treat infections.
About five to eight percent of women experience recurrent vulvovaginal candidiasis (RVVC), defined as four or more yeast infections per year.
About five percent of women with vaginal yeast infections develop recurrent vulvovaginal candidiasis (RVVC), which is defined as four or more symptomatic vaginal yeast infections in a one-year period.
The company unveiled also the results of the largest, international representative epidemiological survey on recurrent vulvovaginal candidiasis (RVVC), saying that 7% of adult women suffer from the disease.